ARMATA PHARMACEUTICALS INC
NYSE: ARMP (Armata Pharmaceuticals, Inc.)
Kemas kini terakhir: 5 jam lalu12.88
1.19 (10.18%)
| Penutupan Terdahulu | 11.69 |
| Buka | 12.10 |
| Jumlah Dagangan | 40,624 |
| Purata Dagangan (3B) | 44,770 |
| Modal Pasaran | 471,830,144 |
| Harga / Buku (P/B) | 2.11 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 May 2026 |
| Margin Keuntungan | -9.07% |
| Margin Operasi (TTM) | -1,668.23% |
| EPS Cair (TTM) | -0.400 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -49.20% |
| Nisbah Semasa (MRQ) | 0.120 |
| Aliran Tunai Operasi (OCF TTM) | -34.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.48 M |
| Pulangan Atas Aset (ROA TTM) | -24.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Armata Pharmaceuticals, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.75 |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 69.55% |
| % Dimiliki oleh Institusi | 2.13% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Seacrest Wealth Management, Llc | 31 Dec 2025 | 40,988 |
| Grey Ledge Advisors, Llc | 31 Dec 2025 | 30,000 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |